Skip to main content


Latest articles

16-09-2020 | Diabetes | News | Article

Insulin injection errors ubiquitous in adults with diabetes

Canadian researchers have identified at least one insulin injection technique error in all people with insulin-dependent diabetes who were surveyed for a study.

15-09-2020 | Diabetes | News | Article

SGLT2 inhibition ‘could overcome diuretic resistance’

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

14-09-2020 | Diabetes | News | Article

Time in range linked to albuminuria reduction

A post-hoc analysis of a prospective study indicates that increased time in range is linked to a reduction in albuminuria in people with type 1 diabetes.

11-09-2020 | Diabetes | News | Article

Moderate alcohol consumption linked to high blood pressure in type 2 diabetes

Both moderate and high alcohol consumption are independently associated with hypertension in people with type 2 diabetes and cardiovascular disease, and the risk rises with increasing consumption, ACCORD study data suggest.

10-09-2020 | Diabetes | News | Article

New-onset type 2 diabetes accompanied by weight loss may point to pancreatic cancer risk

Type 2 diabetes and weight loss are independently associated with an increased risk for pancreatic cancer, and this risk is further elevated when weight loss occurs together with recent-onset diabetes, according to results from a cohort study.

09-09-2020 | Diabetes | News | Article

Weight loss strongest predictor of remission in DiRECT

The strongest predictor of type 2 diabetes remission is weight loss, with other variables only modestly associated with outcome and insufficient to identify people unsuitable for attempting this goal, shows a post-hoc analysis of DiRECT data.

08-09-2020 | Diabetes | News | Article

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

07-09-2020 | Diabetes | News | Article

Type 2 diabetes adversely affects bone mass in youth

Youth with type 2 diabetes have lower areal bone mineral density than those with obesity or who are of normal weight, according to the results of a cross-sectional study.

04-09-2020 | Diabetes | News | Article

FDA okays MiniMed 770G for young children

Click through to read more on this announcement

04-09-2020 | Diabetes | News | Article

High usual HbA1c raises cardiovascular risk in type 2 diabetes

The risk for someone with type 2 diabetes experiencing a cardiovascular disease event increases by 21% for every 1% increase in their usual glycated hemoglobin level above 7.0%, study findings suggest.

04-09-2020 | Diabetes | News | Article

FDA removes amputation Boxed Warning from canagliflozin label

Click through to read more on this announcement

02-09-2020 | Diabetes | News | Article

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

01-09-2020 | Diabetes | News | Article

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

01-09-2020 | Diabetes | News | Article

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

28-08-2020 | Diabetes | News | Article

Early risk for anemia associated with metformin use in type 2 diabetes

Metformin consistently causes an early reduction in hemoglobin and increases the risk for moderate anemia in patients with type 2 diabetes, a MASTERMIND consortium analysis shows.

26-08-2020 | Diabetes | News | Article

​​​​​​​Closed-loop system improves glycemic control in children with type 1 diabetes

Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.

25-08-2020 | Diabetes | News | Article

Voice-enabled CGM benefits blind patients with diabetes

Using voice-enabled continuous glucose monitoring may help improve glycemic control and reduce severe hypoglycemia in legally blind patients with insulin-treated diabetes, US researchers report.

24-08-2020 | Diabetes | News | Article

Multiple factors linked to type 2 diabetes glycemic progression

Extremes of bodyweight and high glycated hemoglobin levels were two of the factors linked to rapid glycemic progression in a study of more than 7000 Chinese people with type 2 diabetes.

21-08-2020 | Diabetes | News | Article

Fasting glucose variability in young adulthood linked to CAC progression in middle age

A prospective study has revealed that greater fasting glucose variability during young adulthood is independently associated with increased risk for coronary artery calcification progression in middle age.

20-08-2020 | Diabetes | News | Article

Collaborative care may improve diabetes, depression management in resource-limited settings

A collaborative care intervention delivered at urban diabetes clinics improves depressive symptoms and cardiometabolic outcomes among people with comorbid diabetes and depression in India, shows the INDEPENDENT trial.